Clinical trialNo phase (not a drug trial)Completed
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable, Unresectable, or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region
- Outcome
- Results posted; single-arm, no comparison
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 1 May 2016
- Ended
- 15 May 2025
- Enrollment
- 36 participants
- Sites
- 2
- Primary outcomes
- Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage)
- Sponsor type
- Academic / other
- Results posted
- 3 November 2025
- Last update
- 3 November 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 3 November 2025
- Primary outcome
- Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage)Hematologic: Lymphocyte Count Decreased: All Eligible Participants: 13.89 (4.41 to 23.37), n = 36Hematologic: White Blood Cell Decreased: All Eligible Participants: 0.00 (0.00 to 0.00), n = 36Gastrointestinal: Nausea: All Eligible Participants: 2.78 (0.00 to 7.28), n = 36Gastrointestinal: Abdominal Pain: All Eligible Participants: 0.00 (0.00 to 0.00), n = 36Gastrointestinal: Diarrhea: All Eligible Participants: 0.00 (0.00 to 0.00), n = 36Gastrointestinal: Bloating: All Eligible Participants: 0.00 (0.00 to 0.00), n = 36Values: percentage of participants, 90% Confidence IntervalTime frame: Up to 90 days after treatment6 of 9 rows shownNo analysis posted for this outcome (outcome 1)
- Participants
- Cohort A: 3 started, 2 completedCohort B: 33 started, 33 completed
- Serious adverse events
- Cohort A: 3 of 3Cohort B: 33 of 33Participants with at least one serious adverse event, of those at risk, as posted
8 secondary outcomes
- Late, Treatment-related Toxicity Rates of Gastritis, Enteritis, Fistula, and Ulcer, or An…
- Gastritis: All Eligible Participants 0.00 (0.00 to 0.00), n=36 [percentage of participants, 90% Confidence Interval] (first of 6 rows)
- OS · Overall Survival
- Cohort B .4849 (.3368 to .6178), n=33 [survival probability, 90% Confidence Interval]
- PFS · Progression-Free Survival
- Cohort B .3939 (.2557 to .5293), n=33 [survival probability, 90% Confidence Interval]
- Metastasis-Free Survival
- Cohort B .4846 (.3368 to .6178), n=33 [survival probability, 90% Confidence Interval]
- Wong-Baker FACES Pain Rating Score
- Before Treatment Score: Cohort A 1.00 (0.00 to 2.50), n=3; Cohort B 2.00 (0.00 to 4.00), n=33 [median score on a scale, Inter-Quartile Range] (first of 3 rows)
- Quality of Life Scores - Global Health Status / Quality of Life
- Global Health Status - Before Treatment: Cohort A 83.33 (83.33 to 83.33), n=2; Cohort B 75.00 (50.00 to 83.33), n=25 [median score on a scale, Inter-Quartile Range] (first of 3 rows)
- Quality of Life Scores - Functional Scales
- Physical Functioning - Before Treatment: Cohort A 76.67 (71.67 to 81.67), n=2; Cohort B 93.33 (86.67 to 100.00), n=25 [median score on a scale, Inter-Quartile Range] (first of 15 rows)
- Quality of Life Scores - Symptom Scales
- Fatigue - Before Treatment: Cohort A 44.44 (33.33 to 55.56), n=2; Cohort B 33.33 (25.00 to 44.44), n=25 [median score on a scale, Inter-Quartile Range] (first of 27 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary cancers who have previously undergone treatment with chemotherapy, surgery, photodynamic therapy, conventionally fractionated radiation treatment, or any combination of these therapies. Primary Objective • To estimate rates of acute (within 3 months of treatment) grade 3 or greater gastrointestinal and hematologic toxicity in patients treated with Linac-based SBRT for pancreatic or periampullary cancers who have previously received other treatment. Secondary Objectives * To estimate rates of late (\> 3 months after treatment) grade 2 gastritis, enteritis, fistula, and ulcer, or any other grade 3 or greater gastrointestinal toxicity in patients treated with Linac-based SBRT for pancreatic or periampullary cancers * To estimate rates of local progression, overall survival, metastasis-free survival, and progression-free survival in patients with pancreatic or periampullary cancers treated with fractionated Linac-based SBRT. * To evaluate the ability of Linac-based SBRT to provide pain control in patients with pain related to a pancreatic or periampullary tumor. * To evaluate quality of life in patients undergoing treatment with Linac-based SBRT for pancreatic or periampullary cancers.
Detailed description public domain (ClinicalTrials.gov)
Patients will receive 5 fractions of 5 gray (Gy) or 6.6 Gy delivered over a five-day period based on whether or not they have received prior radiation therapy to the pancreatic region. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week. Initial patient positioning will be based on volumetric kV (cone-beam computerized tomography) imaging with shifts to bony anatomy as appropriate. Orthogonal kV/MV or kV/kV projection imaging will be used to verify the location of the fiducials prior to delivery of the first treatment beam. A secondary shift based on the location of fiducials may be utilized, as indicated by the position of the fiducials. For free-breathing treatments, kV fluoroscopic images should be obtained to confirm the anticipated position of these fiducials during the entire respiratory cycle. Active monitoring of treatment delivery accuracy will be accomplished using kV and/or MV projection imaging, either immediately before or during all (or a subset of) treatment fields. Patient-specific dosimetric quality assurance (QA) will be performed as per standard practice in the Department of Radiation Oncology, Indiana University School of Medicine.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) [Up to 90 days after treatment]. Number, percentage of participants (90% Confidence Interval). Hematologic: Lymphocyte Count Decreased: All Eligible Participants (n=36): 13.89 (4.41 to 23.37). Hematologic: White Blood Cell Decreased: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Nausea: All Eligible Participants (n=36): 2.78 (0.00 to 7.28). Gastrointestinal: Abdominal Pain: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Diarrhea: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Bloating: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Flatulence: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Gastritis: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Gastrointestinal: Vomiting: All Eligible Participants (n=36): 2.78 (0.00 to 7.28).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Late, Treatment-related Toxicity Rates of Gastritis, Enteritis, Fistula, and Ulcer, or Any Other Gastrointestinal Toxicity (as Raw Percentage) [90 or more days after treatment, up to 7 years]. Number, percentage of participants (90% Confidence Interval). Gastritis: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Enteritis: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Fistula: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Ulcer: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Diarrhea: All Eligible Participants (n=36): 0.00 (0.00 to 0.00). Vomiting: All Eligible Participants (n=36): 0.00 (0.00 to 0.00).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [1 year after treatment]. Number, survival probability (90% Confidence Interval). Cohort B (n=33): .4849 (.3368 to .6178).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival [1 year after treatment]. Number, survival probability (90% Confidence Interval). Cohort B (n=33): .3939 (.2557 to .5293).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Metastasis-Free Survival [1 year after treatment]. Number, survival probability (90% Confidence Interval). Cohort B (n=33): .4846 (.3368 to .6178).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Wong-Baker FACES Pain Rating Score [Baseline (before treatment), Week 1 (during treatment), Week 2 (during treatment), Month 1 (after treatment), and Month 3 (after treatment)]. Median, score on a scale (Inter-Quartile Range). Before Treatment Score: Cohort A (n=3): 1.00 (0.00 to 2.50); Cohort B (n=33): 2.00 (0.00 to 4.00). During Treatment Score: Cohort A (n=3): 2.00 (1.00 to 2.00); Cohort B (n=33): 0.00 (0.00 to 2.00). After Treatment Score: Cohort A (n=3): 2.00 (0.00 to 2.00); Cohort B (n=33): 0.00 (0.00 to 4.00). Analysis, Cohort B: p=0.824; Mixed Models Analysis; other.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Quality of Life Scores - Global Health Status / Quality of Life [Baseline (before treatment), 1 week (during treatment), 2 weeks (during treatment), 1 month (after treatment), 3 months (after treatment), 6 months (after treatment), 9 months (after treatment), and 12 months (after treatment)]. Median, score on a scale (Inter-Quartile Range). Global Health Status - Before Treatment: Cohort A (n=3): 83.33 (83.33 to 83.33); Cohort B (n=33): 75.00 (50.00 to 83.33). Global Health Status - During Treatment: Cohort A (n=3): 83.33 (83.33 to 83.33); Cohort B (n=33): 66.67 (50.00 to 83.33). Global Health Status - After Treatment: Cohort A (n=3): 79.17 (43.75 to 83.33); Cohort B (n=33): 70.83 (50.00 to 83.33). Analysis, Cohort B: p=0.270; Regression, Logistic; other.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Quality of Life Scores - Functional Scales [Baseline (before treatment), 1 week (during treatment), 2 weeks (during treatment), 1 month (after treatment), 3 months (after treatment), 6 months (after treatment), 9 months (after treatment), and 12 months (after treatment)]. Median, score on a scale (Inter-Quartile Range). Physical Functioning - Before Treatment: Cohort A (n=3): 76.67 (71.67 to 81.67); Cohort B (n=33): 93.33 (86.67 to 100.00). Physical Functioning - During Treatment: Cohort A (n=3): 86.67 (86.67 to 88.33); Cohort B (n=33): 86.67 (73.33 to 93.33). Physical Functioning - After Treatment: Cohort A (n=3): 80.00 (73.33 to 96.67); Cohort B (n=33): 86.67 (80.00 to 100.00). Role Functioning - Before Treatment: Cohort A (n=3): 50.00 (41.67 to 58.33); Cohort B (n=33): 83.33 (66.67 to 100.00). Role Functioning - During Treatment: Cohort A (n=3): 75.00 (66.67 to 83.33); Cohort B (n=33): 83.33 (66.67 to 100.00). Role Functioning - After Treatment: Cohort A (n=3): 75.00 (41.67 to 95.83); Cohort B (n=33): 100.00 (66.67 to 100.00). Emotional Functioning - Before Treatment: Cohort A (n=3): 75.00 (70.83 to 79.17); Cohort B (n=33): 83.33 (66.67 to 91.67). Emotional Functioning - During Treatment: Cohort A (n=3): 83.33 (81.25 to 83.33); Cohort B (n=33): 91.67 (75.00 to 100.00). Emotional Functioning - After Treatment: Cohort A (n=3): 75.00 (68.75 to 81.25); Cohort B (n=33): 83.33 (72.92 to 100.00). Cognitive Functioning - Before Treatment: Cohort A (n=3): 91.67 (87.50 to 95.83); Cohort B (n=33): 83.33 (66.67 to 100.00). Cognitive Functioning - During Treatment: Cohort A (n=3): 100.00 (100.00 to 100.00); Cohort B (n=33): 83.33 (83.33 to 100.00). Cognitive Functioning - After Treatment: Cohort A (n=3): 83.33 (70.83 to 95.83); Cohort B (n=33): 83.33 (79.17 to 100.00). Social Functioning - Before Treatment: Cohort A (n=3): 33.33 (33.33 to 33.33); Cohort B (n=33): 66.67 (50.00 to 83.33). Social Functioning - During Treatment: Cohort A (n=3): 83.33 (62.50 to 100.00); Cohort B (n=33): 66.67 (50.00 to 100.00). Social Functioning - After Treatment: Cohort A (n=3): 66.67 (54.17 to 91.67); Cohort B (n=33): 83.33 (66.67 to 100.00). Analysis, Cohort B: p=0.179; Regression, Logistic; other. Analysis, Cohort B: p=0.789; Regression, Logistic; other. Analysis, Cohort B: p=0.303; Regression, Logistic; other. Analysis, Cohort B: p=0.989; Regression, Logistic; other. Analysis, Cohort B: p=0.436; Regression, Logistic; other.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Quality of Life Scores - Symptom Scales [Baseline (before treatment), 1 week (during treatment), 2 weeks (during treatment), 1 month (after treatment), 3 months (after treatment), 6 months (after treatment), 9 months (after treatment), and 12 months (after treatment)]. Median, score on a scale (Inter-Quartile Range). Fatigue - Before Treatment: Cohort A (n=3): 44.44 (33.33 to 55.56); Cohort B (n=33): 33.33 (25.00 to 44.44). Fatigue - During Treatment: Cohort A (n=3): 33.33 (33.33 to 33.33); Cohort B (n=33): 33.33 (22.22 to 55.56). Fatigue - After Treatment: Cohort A (n=3): 44.44 (33.33 to 72.22); Cohort B (n=33): 33.33 (11.11 to 44.44). Nausea and Vomiting - Before Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 16.67). Nausea and Vomiting - During Treatment: Cohort A (n=3): 8.33 (0.00 to 16.67); Cohort B (n=33): 16.67 (0.00 to 16.67). Nausea and Vomiting - After Treatment: Cohort A (n=3): 25.00 (16.67 to 33.33); Cohort B (n=33): 0.00 (0.00 to 16.67). Pain - Before Treatment: Cohort A (n=3): 41.67 (37.50 to 45.83); Cohort B (n=33): 16.67 (0.00 to 33.33). Pain - During Treatment: Cohort A (n=3): 16.67 (16.67 to 20.83); Cohort B (n=33): 33.33 (0.00 to 50.00). Pain - After Treatment: Cohort A (n=3): 33.33 (20.83 to 58.33); Cohort B (n=33): 16.67 (0.00 to 50.00). Dyspnea - Before Treatment: Cohort A (n=3): 16.67 (8.33 to 25.00); Cohort B (n=33): 0.00 (0.00 to 0.00). Dyspnea - During Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 0.00). Dyspnea - After Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 33.33). Insomnia - Before Treatment: Cohort A (n=3): 33.33 (16.67 to 50.00); Cohort B (n=33): 33.33 (0.00 to 33.33). Insomnia - During Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 33.33). Insomnia - After Treatment: Cohort A (n=3): 16.67 (0.00 to 33.33); Cohort B (n=33): 0.00 (0.00 to 33.33). Appetite Loss - Before Treatment: Cohort A (n=3): 16.67 (8.33 to 25.00); Cohort B (n=33): 0.00 (0.00 to 33.33). Appetite Loss - During Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 33.33). Appetite Loss - After Treatment: Cohort A (n=3): 16.67 (0.00 to 58.33); Cohort B (n=33): 0.00 (0.00 to 33.33). Constipation - Before Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 0.00 (0.00 to 33.33). Constipation - During Treatment: Cohort A (n=3): 0.00 (0.00 to 8.33); Cohort B (n=33): 16.67 (0.00 to 33.33). Constipation - After Treatment: Cohort A (n=3): 0.00 (0.00 to 25.00); Cohort B (n=33): 0.00 (0.00 to 0.00). Diarrhea - Before Treatment: Cohort A (n=3): 0.00 (0.00 to 0.00); Cohort B (n=33): 16.67 (0.00 to 33.33). Diarrhea - During Treatment: Cohort A (n=3): 16.67 (0.00 to 33.33); Cohort B (n=33): 0.00 (0.00 to 33.33). Diarrhea - After Treatment: Cohort A (n=3): 16.67 (0.00 to 33.33); Cohort B (n=33): 33.33 (0.00 to 33.33). Financial Difficulties - Before Treatment: Cohort A (n=3): 66.67 (66.67 to 66.